OPP003 📄 Overview Develop a novel implantable device that selectively releases specific neurotransmitters or neuromodulators (e.g., serotonin, dopamine agonists, GABA) into targeted brain regions implicated in severe, treatment-resistant psychiatric conditions like major depression, OCD, or PTSD. The system could be triggered by external signals (e.g., patient-reported symptoms via a mobile app, or AI-detected physiological markers from a wearable) allowing for on-demand, precise neuromodulation. Key technologies: 👤 Target users: 👍 Benefits Rapid and sustained symptomatic relief for severe psychiatric conditions • Reduced need for systemic psychotropic medications and associated side effects • Highly personalized and responsive treatment based on patient's real-time needs • Potential for remission in otherwise untreatable cases Use bullets or new lines. 👎 Challenges Ethical implications of directly modulating brain chemistry for mental health • Precise targeting and minimizing off-target effects in complex neural circuits • Safety of long-term neurotransmitter exposure • Patient acceptance of an invasive brain procedure for a psychiatric condition • Reliability of patient-reported triggers and wearable-derived biomarkers 📋 Regulatory & Validation Requires stringent ethical review and informed consent processes for vulnerable populations • Robust pre-clinical data on behavioral and neurological effects of modulation • Long-term safety studies focusing on potential for abuse, dependence, or unintended psychiatric effects • Clear guidelines for 'patient-initiated' dosing within safety parameters